FDA could have a new combination products approval pathway ready for congressional consideration within a year, commissioner nominee Robert Califf said.
During his Nov
Califf Supports Combo Products Pathway At Confirmation Hearing
FDA's concepts for new pathway could be ready for congressional scrutiny within a year.
More from United States
More from North America
• By
New draft guidance on the third cycle of Medicare drug price negotiations goes against Merck and BMS expectations for their cancer drugs. The guidance also tackles Part B and renegotiated prices for the first time.
• By
A professional slide deck for the drospirenone/estetrol oral contraceptive inappropriately suggests it is safer than other estrogen-containing products and understates risks, Office of Prescription Drug Promotion said in the first “untitled” letter issued since reductions-in-force.
• By
Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.